Surgeons must prioritize evaluating specific resection margins in pancreatic cancer for better patient outcomes.

• Three key margins—superior-mesenteric vein (HR 1.48), medial (HR 1.92), and posterior (HR 1.65)—are significantly linked to disease-free survival.
• R1 status worsens survival in gemcitabine-treated patients (HR 1.97) but not with mFOLFOXIRI.

Aim for thorough margin assessment focusing on these three areas to enhance surgical decision-making and patient prognoses.